- Home
- WALD vs ALXO Comparison
WALD vs ALXO Comparison
Compare WALD & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WALD | ALXO |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.3M | 205.9M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WALD | ALXO |
|---|---|---|
| Price | $1.13 | $1.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.00 | ★ $3.50 |
| AVG Volume (30 Days) | 257.3K | ★ 667.9K |
| Earning Date | 03-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.89 | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $1.03 |
| 52 Week High | $3.22 | $2.66 |
Technical Indicators
Market Signals| Indicator | WALD | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 27.58 | 44.21 |
| Support Level | $0.86 | $1.56 |
| Resistance Level | $1.18 | $2.17 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 16.67 | 28.57 |
Price Performance
Historical ComparisonAbout WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.